Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab Combinations in Metastatic Triple Negative Breast Cancer
NCT03971409Phase 2Active, not recruiting
- Sponsor
- Laura Huppert
- Start
- Jul 2019
- Primary completion
- Jan 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of avelumab in triple-negative breast cancer (TNBC), sponsored by Laura Huppert. Started Jul 2019; status: active, not recruiting.
02
Drugs
avelumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03971409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03971409.